NCT06033742

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HS-10374 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 84 (actual)
• Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this first-in-human study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of HS-10374 in healthy subjects.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	HS-10374 tablets	Single or multiple dosing of HS-10374 orally in a fasting state
DRUG	HS-10374-matched placebo tablets	Single or multiple dosing of HS-10374-matched placebo orally in a fasting state

Timeline

• Start date: 2021-11-13
• Primary completion: 2023-03-24
• Completion: 2023-03-24
• First posted: 2023-09-13
• Last updated: 2023-09-13

Locations

1 site across 1 country: China